After obtaining all required regulatory authorizations in the UK for the clinical study MIN-001-1203, Laminar Pharma confirmed the activation of the first site in Sutton, Surrey (UK), which will be recruiting participants from today. The other two sites taking part in the first part of the study (in Newcastle and Barcelona) are expected to be also active from the first week of June. The hospital in Zurich will be joining the study in the second phase of the trial, once the dose escalation phase is completed. Up to 50 patients with advanced solid tumors, including malignant glioma, are expected to be enrolled in this clinical trial.

Laminar Pharma’s R&D program in Oncology with 2OHOA was selected to present at BioTrinity 2013, the annual conference created by OBN which features a hand-picked showcase of Europe’s leading emerging life sciences companies, as more than 850 delegates from 30 countries are expected to attend this 2013 edition.

Vicenç Tur, CEO of Laminar Pharma, presented in the Company Showcase (oncology track) and actively participated in this year’s edition of Biotrinity in Newbury (UK) with the objective of pursuing Laminar Pharma’s ongoing contacts with key industry players as well as to explore additional collaborations with investors and new potential industry partners.